Recombinant Full Length Mouse Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor(Adcyap1R1) Protein, His-Tagged
Cat.No. : | RFL-15503MF |
Product Overview : | Recombinant Full Length Mouse Pituitary adenylate cyclase-activating polypeptide type I receptor(Adcyap1r1) Protein (P70205) (21-496aa), fused to N-terminal His tag, was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
Source : | E.coli expression system |
Species : | Mus musculus (Mouse) |
Tag : | His |
Form : | Lyophilized powder |
Protein length : | Full Length (21-496) |
AA Sequence : | MHSDCIFKKEQAMCLERIQRANDLM GLNESSPGCPGMWDNITCWKPAQIG EMVLVSCPEV FRIFNPDQVWMTETIGDSGFADSNS LEITDMGVVGRNCTEDGWSEPFPHY FDACGFDDYE PESGDQDYYYLSVKALYTVGYSTSL VTLTTAMVILCRFRKLHCTRNFIHM NLFVSFMLRA ISVFIKDWILYAEQDSSHCFVSTVE CKAVMVFFHYCVVSNYFWLFIEGLY LFTLLVETFF PERRYFYWYTIIGWGTPTVCVTVWA VLRLYFDDAGCWDMNDSTALWWVIK GPVVGSIMVN FVLFIGIIIILVQKLQSPDMGGNES SIYFSCVQKCYCKPQRAQQHSCKMS ELSTITLRLA RSTLLLIPLFGIHYTVFAFSPENVS KRERLVFELGLGSFQGFVVAVLYCF LNGEVQAEIK RKWRSWKVNRYFTMDFKHRHPSLAS SGVNGGTQLSILSKSSSQLRMSSLP ADNLAT |
Purity : | Greater than 90% as determined by SDS-PAGE. |
Applications : | SDS-PAGE |
Notes : | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Storage : | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
Storage Buffer : | Tris/PBS-based buffer, 6% Trehalose, pH 8.0 |
Reconstitution : | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference. |
Gene Name : | Adcyap1r1 |
Synonyms : | Adcyap1r1; Pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP type I receptor; PACAP-R-1; PACAP-R1 |
UniProt ID : | P70205 |
Gene Name : | Adcyap1r1 |
Synonyms : | Adcyap1r1; Pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP type I receptor; PACAP-R-1; PACAP-R1 |
UniProt ID : | P70205 |
Products Types
◆ Recombinant Protein | ||
ADCYAP1R1-177R | Recombinant Rat ADCYAP1R1 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADCYAP1R1-3708C | Recombinant Chicken ADCYAP1R1 | +Inquiry |
ADCYAP1R1-521R | Recombinant Rat ADCYAP1R1 Protein | +Inquiry |
ADCYAP1R1-510H | Recombinant Human ADCYAP1R1 Protein, Fc-tagged | +Inquiry |
ADCYAP1R1-335H | Recombinant Human ADCYAP1R1 Protein, GST-tagged | +Inquiry |
◆ Lysates | ||
ADCYAP1R1-1642HCL | Recombinant Human ADCYAP1R1 cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-2175 | ADCYAP1R1 CHO-K1 β-Arrestin GPCR Assay Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (14)
Ask a questionADCYAP1R1 protein therapy is not currently approved by the FDA for the treatment of mental health disorders. It is still in the experimental stages of development and clinical trials.
Side effects of ADCYAP1R1 protein therapy may include injection site reactions, fatigue, and dizziness. However, side effects are generally mild and resolve quickly.
ADCYAP1R1 protein therapy may be particularly effective in treating mental health disorders in individuals who have not responded to or cannot tolerate standard treatments such as psychotherapy or medication. Additionally, it may be effective in individuals with PTSD or depression who have elevated levels of stress hormones. Further research is needed to identify specific patient populations who may benefit from this treatment.
One of the main challenges associated with the development and use of ADCYAP1R1 protein therapy is the need for further research to determine its therapeutic potential and safety. Additionally, there may be issues related to cost and access to this type of treatment.
ADCYAP1R1 protein therapy is administered through intravenous injection, nasal spray, or subcutaneous injection.
Currently, there are no alternative treatments that work similarly to ADCYAP1R1 protein therapy. However, there are other treatments such as medication, therapy, and lifestyle changes that have been shown to be effective in the treatment of mental health disorders.
ADCYAP1R1 protein therapy is not a cure for mental health disorders. It is a potential treatment option that may provide relief from symptoms and improve quality of life for individuals with certain conditions. Regular and ongoing treatment may be necessary for long-term management of mental health disorders.
The time it takes for ADCYAP1R1 protein therapy to start working can vary among individuals, and studies examining its efficacy are ongoing. However, some studies have shown that improvements in symptoms may be seen within the first weeks of treatment.
ADCYAP1R1 protein therapy has shown promising results in the treatment of generalized anxiety disorder. However, more research is needed to determine its effectiveness for other types of anxiety disorders, such as panic disorder or social anxiety disorder.
ADCYAP1R1 protein therapy has shown potential for treating mental health conditions such as anxiety, post-traumatic stress disorder (PTSD), and depression. It has also been studied for its potential use in the treatment of Parkinson's disease and chronic pain.
ADCYAP1R1 protein therapy works by targeting a specific receptor in the brain called the pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1R). This receptor is involved in many important brain processes, including stress response, mood regulation, and memory formation.
ADCYAP1R1 protein therapy is not currently a first-line treatment for anxiety disorders. It is considered a second-line or adjunct treatment option for patients who have not responded to or cannot tolerate standard treatments such as antidepressants or benzodiazepines.
The potential benefits of ADCYAP1R1 protein therapy include the reduction of anxiety symptoms, such as excessive worry, restlessness, and difficulty sleeping.
The side effects of ADCYAP1R1 protein therapy are not well-known because it is still in the experimental stages of development. However, potential side effects could include headache, fatigue, nausea, and allergic reactions.
Ask a Question for All Adcyap1r1 Products
Required fields are marked with *
My Review for All Adcyap1r1 Products
Required fields are marked with *
Inquiry Basket